Related Experiment Videos
Third generation oral cephalosporins: comparative in vitro kinetics
A Speciale1, G Blandino, G Nicoletti
1Institute of Microbiology, University of Catania, Italy.
Journal of Chemotherapy (Florence, Italy)
|May 1, 1995
Summary
Cefetamet-pivoxil demonstrates potent in vitro bactericidal activity against key respiratory pathogens like H. influenzae and S. pneumoniae. Its killing kinetics are comparable to cefixime and ceftibuten, suggesting a promising role in treating respiratory infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Respiratory tract infections (RTIs) are commonly caused by bacteria.
- Novel antibiotics are needed to combat resistant pathogens.
- Cefetamet-pivoxil is an oral cephalosporin with potential for treating RTIs.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity of cefetamet-pivoxil.
- To compare the bactericidal kinetics of cefetamet-pivoxil with cefixime and ceftibuten.
- To assess efficacy against common respiratory pathogens.
Main Methods:
- Time-kill studies were conducted using various bacterial inocula (10^5 to 10^9 CFU/ml).
- Antibiotic concentrations tested were 1x MIC and 4x MIC.
- Bacterial viability was determined by serial dilutions and plating at regular intervals.
Main Results:
- Cefetamet-pivoxil achieved ≥99.9% killing of H. influenzae and M. catarrhalis within 4 hours at 4x MIC and 10^5 CFU/ml.
- Significant reductions were observed for E. coli, K. pneumoniae, S. pneumoniae, and S. pyogenes within 2-6 hours.
- Effective killing was maintained across different inocula and at lower concentrations.
Conclusions:
- Cefetamet-pivoxil exhibits potent and rapid bactericidal activity against a range of respiratory pathogens.
- Its performance favorably compares to cefixime and ceftibuten.
- Cefetamet-pivoxil shows potential as a valuable oral cephalosporin for treating respiratory tract infections.